Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 404-411

  Jiang, Donghai ^a   Sui, Meihua ^b   Zhong, Wangyan ^a   Huang, Yuan ^a   Fan, Weimin ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dose dense chemotherapy; Dose escalation chemotherapy; Invasion; Migration; Multidrug resistance

Indexed keywords

FULVESTRANT; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PACLITAXEL; PHENOTYPE;

EID: 84878259408     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.059     Document Type: Article

References (36)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
2. Johnston S.R. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur. J. Cancer 2011, 47(Suppl 3):S38-47.
3. Rivera E., Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010, 12(Suppl 2):S2.
4. Murphy C.G., Khasraw M., Seidman A.D. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast cancer Res. Treat. 2010, 122:177-179.
5. Watson M.B., Lind M.J., Cawkwell L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs 2007, 18:749-754.
6. Eniu A., Palmieri F.M., Perez E.A. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005, 10:665-685.
7. Kaklamani V.G., Gradishar W.J. Adjuvant therapy of breast cancer. Cancer Invest. 2005, 23:548-560.
8. Skipper H.E. Laboratory models: some historical perspective. Cancer Treat. Rep. 1986, 70:3-7.
9. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., Davidson N.E., Martino S., Livingston R., Ingle J.N., Perez E.A., Carpenter J., Hurd D., Holland J.F., Smith B.L., Sartor C.I., Leung E.H., Abrams J., Schilsky R.L., Muss H.B., Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J. Clin. Oncol. 2003, 21:1431-1439.
10. Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., Tsuda H., Sugiyama T., Kodama S., Kimura E., Ochiai K., Noda K. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
11. John M., Hinke A., Stauch M., Wolf H., Mohr B., Hindenburg H.J., Papke J., Schlosser J. Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study. BMC Cancer 2012, 12:165.
12. Seidman A.D., Hudis C.A., Albanell J., Tong W., Tepler I., Currie V., Moynahan M.E., Theodoulou M., Gollub M., Baselga J., Norton L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 1998, 16:3353-3361.
13. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 2001, 19:4216-4223.
14. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
15. Al-Ejeh F., Smart C.E., Morrison B.J., Chenevix-Trench G., Lopez J.A., Lakhani S.R., Brown M.P., Khanna K.K. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011, 32:650-658.
16. Gerber B., Freund M., Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch. Arztebl. Int. 2010, 107:85-91.
17. Sui M., Huang Y., Park B.H., Davidson N.E., Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007, 67:5337-5344.
18. Sui M., Chen F., Chen Z., Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int. J. Cancer 2006, 119:712-717.
19. Sui M., Jiang D., Hinsch C., Fan W. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res. Treat. 2010, 121:335-345.
20. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
21. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009, 109:2989-3011.
22. Zhu X., Sui M., Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 2005, 25:1953-1962.
23. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
24. Grossi A., Biscardi M. Reversal of MDR by verapamil analogues. Hematology 2004, 9:47-56.
25. King C.E., Cuatrecasas M., Castells A., Sepulveda A.R., Lee J.S., Rustgi A.K. LIN28B promotes colon cancer progression and metastasis. Cancer Res. 2011, 71:4260-4268.
26. Khan N., Mukhtar H. Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev. 2010, 29:435-445.
27. Achuthan S., Santhoshkumar T.R., Prabhakar J., Nair S.A., Pillai M.R. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 2011, 286:37813-37829.
28. Konstantinidou A.E., Korkolopoulou P., Patsouris E. Apoptotic markers for tumor recurrence: a minireview. Apoptosis 2002, 7:461-470.
29. Song J., Shih Ie M., Salani R., Chan D.W., Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin. Cancer Res. 2007, 13:6842-6849.
30. Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., Sarkar F.H. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat. 2010, 13:109-118.
31. Di Nicolantonio F., Mercer S.J., Knight L.A., Gabriel F.G., Whitehouse P.A., Sharma S., Fernando A., Glaysher S., Di Palma S., Johnson P., Somers S.S., Toh S., Higgins B., Lamont A., Gulliford T., Hurren J., Yiangou C., Cree I.A. Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5:78.
32. Yu D.S., Ma C.P., Chang S.Y. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance. Urol. Res. 2000, 28:86-92.
33. Benavente S., Huang S., Armstrong E.A., Chi A., Hsu K.T., Wheeler D.L., Harari P.M. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Cancer Res. 2009, 15:1585-1592.
34. Smith V., Rowlands M.G., Barrie E., Workman P., Kelland L.R. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin. Cancer Res. 2002, 8:2002-2009.
35. Takemura Y., Kobayashi H., Gibson W., Kimbell R., Miyachi H., Jackman A.L. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Int. J. Cancer 1996, 66:29-36.
36. Balis F.M., Holcenberg J.S., Bleyer W.A. Clinical pharmacokinetics of commonly used anticancer drugs. Clin. Pharmacokinet. 1983, 8:202-232.